comparemela.com
Home
Live Updates
Astellas XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting : comparemela.com
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a...
Related Keywords
Japan ,
Tokyo ,
Canada ,
United States ,
Barcelona ,
Comunidad Autonoma De Cataluna ,
Spain ,
American ,
America ,
Antonio Alcaraz ,
Ahsan Arozullah ,
European Union ,
Drug Administration ,
European Association Of Urology ,
European Commission ,
Department Of Urology ,
American Society Of Clinical Oncology ,
University Hospital Clinic Of Barcelona ,
Committee For Medicinal Products Human Use ,
European Medicines Agency ,
Astellas Pharma Inc ,
Prnewswire Astellas Pharma Inc ,
Head Of Oncology Development ,
European Association ,
University Hospital Clinic ,
Europa Uomo ,
Senior Vice President ,
Oncology Development ,
Medicinal Products ,
Human Use ,
Receives Positive ,
Medicines Agency Validates Type ,
Non Metastatic Hormone Sensitive Prostate Cancer ,
High Risk Biochemical ,
Pfizer Led Phase ,
South America ,
Important Safety Information ,
Product Characteristics ,
Focus Area Approach ,
Biochemically Recurrent Prostate ,
Clin Pract ,
Prostate Cancer ,
comparemela.com © 2020. All Rights Reserved.